BUFFALO, N.Y., Dec. 14, 2017 /PRNewswire/ -- Tactiva Therapeutics, Inc., a development stage company targeting a broad range of cancers, announced today that management will present at Biotech Showcase 2018 to be held in San Francisco, California January 8-10, 2018.
Matt Colpoys, CEO of Tactiva Therapeutics, is scheduled to present on Tuesday, January 9, 2018 at 09:30 AM PST.
For more information about the company please visit the company website at www.tactivatherapeutics.com.
Tactiva is a development stage immuno-oncology company with a unique approach to adoptive T-cell therapy. Tactiva's dual enhanced adoptive cell therapy (DEACT™) approach utilizes engineered T cells to attain a durable response in the treatment of cancer. More information about the company, its technology, and products can be found on its web site atwww.tactivatherapeutics.com.
SOURCE Tactiva Therapeutics